OKTA +16.7%, FIVE +9.4%, PVH +8.7% (also extends license agreements with GIII), SNPS +8.1%, SPLK +7.8%, NTNX +4.4%, KR +3.3%, TGLS +3.2% (guidance), PSTG +2.8%, NCNO +2.2% (also Bank of New Zealand selects nCino Bank Operating System), TD +2.1%
Other news:
ARCE +13.4% (receives Non-Binding Going Private Proposal for $11.00 per share in cash)
OFIX +7.4% (receives competing takeover bid from private equity)
CTXR +6.8% (receives FDA acceptance for BLA of denileukin diftitox)
RGR +5.6% (declares special dividend of $5.00/sh)
ONCY +5.1% (receives FDA Fast Track designation for the treatment of advanced/metastatic pancreatic cancer)
RLYB +4.9% (Rallybio and AbCellera (ABCL) announce strategic alliance to discover develop and commercialize novel antibody-based therapeutics for rare diseases)
AUPH +2.3% (UK grants Great Britain marketing authorization of LUPKYNIS)
INVA +2.1% (FDA accepts Priority Review of NDA for Sulbactam-Durlobactam)
AJRD +1.9% (awarded a $240 mln contract modification from Missile Defense Agency)
ABCL +1.6% (Rallybio and AbCellera (ABCL) announce strategic alliance to discover develop and commercialize novel antibody-based therapeutics for rare diseases)
Analyst comments:
ALT +4.6% (initiated with a Buy at Goldman)
ACRS +0.9% (initiated with a Buy at Goldman)
DAWN +0.9% (initiated with a Buy at BofA Securities)
